Polaris Market Research & Consulting ’s Post

Deubiquitinating enzymes (DUBs) are a family of peptidases that cleave ubiquitin from proteins and play a pivotal role in the pathogenesis of various diseases, including cancer, neurodegenerative disorders, and immune dysfunctions. They detach ubiquitin molecules from protein substrates or disassemble ubiquitin chains. This precise regulation by DUBs ensures the proper functioning of cellular processes and prevents the accumulation of ubiquitinated proteins that could lead to pathological states. The future of DUB research is bright, with the anticipation of discovering safe and efficacious inhibitors for cancer therapy and beyond. Biortus, as our reliable Biologics supplier, provides a diverse array of DUBs family members, including Ubiquitin-Specific Proteases (USPs), Ovarian Tumor Proteases (OTUs), and Ubiquitin Carboxyl-Terminal Hydrolases (UCHs). Leveraging cutting-edge technologies for protein preparation and structural analysis, Biortus ensures the highest standards of purity and functionality in its offerings, supporting researchers in uncovering DUBs' roles in diseases. www.biortususa.com Chemspace is a unique platform, where you can search in 486K+ Biologics, including DUBs, and fulfill your needs in biological services. https://lnkd.in/e6ucVtJW #chemspace #biortus #openscience #research #science #drugdiscovery #chemicals #medicinalchemistry #drugdevelopment #chemistry #researchanddevelopment #search #chemicalindustry #science #structures 

Ong ST, Thomas G, Kannan S, Her Z, Ng XR, Chew X, Nguyen HM, Wulff H, Verma C, Chen Q, Ahmed M, Chandy KG. Novel Inhibitors of the Calcium-Activated K+ Channel KCa3.1 to Treat Non-Alcoholic Fatty Liver Disease and Liver Fibrosis. Biophysical Journal 116(3):249a, February 2019, DOI: 10.1016/j.bpj.2018.11.1362. This work discusses the potential of KCa3.1 inhibitors in treating non-alcoholic fatty liver disease (NAFLD) and liver fibrosis. The researchers screened a library of compounds and identified several novel inhibitors of KCa3.1, which demonstrated promising in vitro and in vivo results. In summary, inhibitors discussed in this work could be used as a potential therapeutic strategy for NAFLD and liver fibrosis. Read the article here: https://lnkd.in/dSPUeZBs #metabolism

Could gut bacteria influence immunotherapy outcomes? Join our webinar with Rachel Newsome, PhD on Feb. 21 to learn about an exciting study linking improved anti-PD-1 therapy response in NSCLC patients to a gut microbiome enhanced with Bacteroides species. A novel Bacteroides metabolite was discovered that stimulates IFNγ production in CD8+ T cells and, when combined with anti-PD-1 treatment, reduced NSCLC tumors significantly in a mouse model. Learn about the cultivation methods that enabled this discovery and empower other microbiome-based drug development. Make sure to save your seat for this informative discussion:  https://hubs.li/Q02kgmYw0  #MicrobialIsolation #Immunotherapy #Microbiome #Webinar #DrugDiscovery #HighThroughputCultivation #Culturomics #Prospector 

#HumanMicroglia for anti-neuroinflammatory potential therapeutic testing #neuroinflammation #microglia #cytokines To investigate the impact of novel therapeutics on microglial function, Celentyx has developed and optimised a human monocyte-derived microglial model whereby human monocytes are differentiated in the presence of a cocktail of brain-relevant cytokines. The differentiated cells express the phenotypic markers of microglia and display characteristic microglial function (e.g. see phagocytic activity [https://lnkd.in/dg9eRHZU], cytokine release). As an exemplar of function, from a 42-plex Luminex panel assessment, we illustrate below the release and inhibition of IL-1β; a key driver of neuroinflammation. Using various stimuli to trigger NLRP3-dependent or -independent activation, Celentyx's human micoglia assay has been used for the characterisation of biologic and small molecule modulators of microglial cytokine release in screening, potency and bench-marking assays. https://lnkd.in/dEs3vp5R #ImmunologyCRO John Gordon, Professor Nicholas Barnes PhD, FBPhS, Omar Qureshi, Catherine Brady

4D Molecular Therapeutics announced positive interim data from the phase 2 PRISM clinical trial evaluating intravitreal 4D-150 in wet age-related macular degeneration (#AMD) patients with severe disease activity and a high treatment burden during the #Angiogenesis, Exudation, and Degeneration 2024 #conference. The data was presented by Dr. Arshad M. Khanani, and it consisted of 24-week results from the randomized phase 2 dose expansion cohort of the #PRISM clinical trial. #AMD #wAMD #MacularDegeneration #IntravitrealInjection #IVI #IVT #neovascularAMD #nAMD 

Progress on using alternative E3 ligases to VHL and CRBN for Targeted Protein Degradation (via PROTACs) - a review. PROTACs (PROteolysis TArgeting Chimeras) are bifunctional small molecules that bind to a target protein on one side and an E3 ligase on the other. This brings the E3 ligase to the target, promotes ubiquitylation and results in degradation of the target by the proteasome. This can be an effective way to design degrader drugs to proteins that have been difficult to inhibit. This also results in a "catalytic" molecule, where a single PROTAC can be re-used and result in the degradation of multiple individual target proteins. There approximately 600 E3 ligases in humans, but two of these are overwhelming used for PROTAC (PROteolysis TArgeting Chimera) development. Using different ligases could result in more potential target proteins, but also allow tissue (or cancer) specific degradation of targets, due to differential E3 expression profiles. This review covers recent progress using alternative E3 ligases for PROTAC development, including the development of covalent degraders, resulting in a binary, rather than ternary interaction. Lahore University of Management Sciences, Goethe University Frankfurt, The Structural Genomics Consortium (SGC), DKFZ German Cancer Research Center #e3ligase #protac #drugdiscovery #smallmolecule #targetedproteindegradation #cancer

Could a patient’s gut microbiome influence how they will respond to immunotherapy? Watch an on-demand presentation by Rachel Newsome, PhD, featuring the findings from a study of Bacteroides-enhanced gut microbiomes associated with an enhanced response to anti-PD-1 therapy in NSCLC patients. In the talk, Rachel details how the characterization of live Bacteroides isolates led to the discovery of a novel influential metabolite that stimulates IFNγ in CD8+ T cells, and in combination with anti-PD-1 therapy, significantly reduces tumor growth in a NSCLC mouse model. Learn about the high-throughput isolation and cultivation methods that, not only enabled this discovery, but can empower any microbiome-based product or drug development program. Watch now! https://hubs.li/Q02nhmGJ0 #MicrobialIsolation #Immunotherapy #Microbiome #Webinar #DrugDiscovery #HighThroughputCultivation #Culturomics #Prospector

Peptide Analysis is essential for understanding the role of peptides in various biological processes, including enzymatic activity and hormone regulation. Through advanced bioanalytical methods, researchers at Veeda investigate the presence, concentration, and behaviour of peptides in biological samples, providing critical insights into both physiological and pathological conditions.   Veeda's research team excels in peptide bioanalysis, supporting the development of peptide-based drugs for diseases such as cancer, diabetes, and cardiovascular disorders.   Here's an overview of different array of techniques and methods Veeda Group uses for Accurate Quantification and Analysis of Peptides   To know more about our Bioanalytical solutions write to us at info@veedacr.com or visit us at www.veedacr.com   Partners in creating a healthier tomorrow. #VeedaGroup #VeedaCR #Veeda #PeptideAnalysis #BioanalyticalDepartment #BioanalyticalSolutions #PeptideBioanalysis

#nanoemulsions #CNS #RNA | 𝗔𝗿𝗲 𝗜𝗼𝗻𝗶𝘇𝗮𝗯𝗹𝗲 𝗡𝗮𝗻𝗼𝗲𝗺𝘂𝗹𝘀𝗶𝗼𝗻𝘀 𝘁𝗵𝗲 𝗙𝘂𝘁𝘂𝗿𝗲 𝗶𝗻 𝗖𝗡𝗦 𝗱𝗿𝘂𝗴 𝗱𝗲𝗹𝗶𝘃𝗲𝗿𝘆? Lipid nanoparticles (LNPs) currently dominate the RNA delivery landscape; however, their limited diffusivity hampers targeted tissue dissemination, and, hence, their capacity for intracellular drug delivery. This is especially relevant for tissues such as the central nervous system (CNS), where overcoming proactive brain barriers is crucial for the efficacy of genetic therapeutics. This research aimed to create ionizable #nanoemulsions (#iNEs), a new generation of #RNA delivery systems with enhanced diffusivity. The developed iNEs, consisting of a combination of C12–200, DOPE, Vitamin E, and DMG-PEG, 𝘄𝗶𝘁𝗵 𝗮 𝘀𝗶𝘇𝗲 𝗯𝗲𝗹𝗼𝘄 𝟭𝟬𝟬 𝗻𝗺, 𝗻𝗲𝘂𝘁𝗿𝗮𝗹 𝘀𝘂𝗿𝗳𝗮𝗰𝗲 𝗰𝗵𝗮𝗿𝗴𝗲, 𝗮𝗻𝗱 𝗵𝗶𝗴𝗵 𝗥𝗡𝗔 𝗹𝗼𝗮𝗱𝗶𝗻𝗴 𝗰𝗮𝗽𝗮𝗰𝗶𝘁𝘆, 𝘀𝗵𝗼𝘄𝗲𝗱 𝗲𝘅𝗰𝗲𝗹𝗹𝗲𝗻𝘁 𝗰𝗲𝗹𝗹 𝘃𝗶𝗮𝗯𝗶𝗹𝗶𝘁𝘆 𝗮𝗻𝗱 𝘁𝗿𝗮𝗻𝘀𝗳𝗲𝗰𝘁𝗶𝗼𝗻 𝗲𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝗰𝘆 𝗶𝗻 𝘃𝗮𝗿𝗶𝗼𝘂𝘀 𝗰𝗲𝗹𝗹𝘂𝗹𝗮𝗿 𝗺𝗼𝗱𝗲𝗹𝘀, 𝗶𝗻𝗰𝗹𝘂𝗱𝗶𝗻𝗴 𝗻𝗲𝘂𝗿𝗼𝗻𝘀, 𝗮𝘀𝘁𝗿𝗼𝗰𝘆𝘁𝗲𝘀, 𝗮𝗻𝗱 𝗺𝗶𝗰𝗿𝗼𝗴𝗹𝗶𝗮. 𝗦𝘂𝗯𝘀𝗲𝗾𝘂𝗲𝗻𝘁𝗹𝘆, #𝗶𝗡𝗘𝘀 𝗰𝗼𝗻𝘁𝗮𝗶𝗻𝗶𝗻𝗴 #𝗺𝗥𝗡𝗔 #𝗚𝗙𝗣 𝘄𝗲𝗿𝗲 𝘁𝗲𝘀𝘁𝗲𝗱 𝗳𝗼𝗿 #𝗖𝗡𝗦 𝘁𝗿𝗮𝗻𝘀𝗳𝗲𝗰𝘁𝗶𝗼𝗻, 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝗶𝗻𝗴 𝘁𝗵𝗲𝗶𝗿 𝗲𝘅𝗰𝗲𝗽𝘁𝗶𝗼𝗻𝗮𝗹 𝗱𝗶𝗳𝗳𝘂𝘀𝗶𝘃𝗶𝘁𝘆 𝗮𝗻𝗱 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝘃𝗲 𝘁𝗿𝗮𝗻𝘀𝗳𝗲𝗰𝘁𝗶𝗼𝗻 𝗼𝗳 𝗻𝗲𝘂𝗿𝗼𝗻𝘀 𝗳𝗼𝗹𝗹𝗼𝘄𝗶𝗻𝗴 𝗶𝗻𝘁𝗿𝗮-𝗽𝗮𝗿𝗲𝗻𝗰𝗵𝘆𝗺𝗮𝗹 𝗮𝗱𝗺𝗶𝗻𝗶𝘀𝘁𝗿𝗮𝘁𝗶𝗼𝗻. Kudos to authors Mireya L. Borrajo, Aloia Quijano Ocampo, Philipp Lapuhs, @Ana Rodriguez-Perez, Shubaash Anthiya, @José Labandeira-Garcia, @Rita Valenzuela, and Maria Jose Alonso. Check here for more: https://lnkd.in/gNXuWQ6h

Number 1️⃣ is always special 🌟. I am very excited to share my first publication as a corresponding author in the Journal of Food and Agriculture, which has an impact factor of 4.1 and is a Q1 journal 🤩. Special mention: it is one of the oldest journals, publishing articles for over 70 years. Evodiamine is a bioactive alkaloid from Evodia rutaecarpa with various pharmacological effects, including anti-cancer. It faces clinical challenges due to low solubility, poor bioavailability, and toxicity, necessitating the development of improved drug delivery systems for enhanced solubility, permeability, stability, and controlled release. This review has discussed various nano/microcarriers for delivering evodiamine for enhanced cancer therapy. #Evodimine #Cancer #Drugdelivery #Wiley #JSFA For more information, visit the link below: